Determinants of Influenza Vaccine Reluctance in Cancer Patients: A Multicenter Cross-Sectional Analysis Utilizing the Health Belief Model - Top-Institutions - MDSpire

Determinants of Influenza Vaccine Reluctance in Cancer Patients: A Multicenter Cross-Sectional Analysis Utilizing the Health Belief Model

  • By

  • Qinghua Dong

  • Yiwei Luo

  • Xiaoyu Tang

  • Minye Li

  • Dianjie Chen

  • Zhengji He

  • Qun Xiao

  • Chen Zhi

  • Min Zhu

  • Hui Ma

  • January 24, 2026

  • 0 min

Share

Top Institutions in Pulmonary

Brief introduction explaining scope and methodology.

  • #1

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Infectious Diseases
    • Immunology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Infectious Diseases
    • Behavioral Medicine

  • #3

    Fred Hutchinson Cancer Center
    Fred Hutchinson Cancer Center

    Seattle, WA

    Key Differentiators

    • Oncology
    • Immunology
    • Epidemiology

  • #4

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Oncology
    • Public Health

  • #5

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Immunology
    • Behavioral Science

Original Source(s)

Determinants of Influenza Vaccine Reluctance in Cancer Patients: A Multicenter Cross-Sectional Analysis Utilizing the Health Belief Model

  • by Qinghua Dong, Yiwei Luo, Xiaoyu Tang, Minye Li, Dianjie Chen, Zhengji He, Qun Xiao, Chen Zhi, Min Zhu, Hui Ma

  • January 24, 2026

Related Content

Effectiveness of COVID-19 Vaccines in Lung Cancer Patients: Navigating Challenges During the Omicron Variant Surge

Surveillance of Measles and Rubella in Bagmati Province, Nepal: An Analysis of Facilitators and Challenges Through Mixed Methods Research

FDA will consider Moderna's mRNA flu vaccine after all